Amivantamab

Phase 2

AstraZeneca PLC (AZN)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q4 '27

AZNPhase 2$256.5B

Amivantamab Phase 2 Est. Readout

Amivantamab• Non-Small Cell Lung Cancer (NSCLC)60

Q4 2027~QEstimated

CT.gov

00%

Competitive Landscape

3 competitors in Non-Small Cell Lung Cancer (NSCLC)

Drug Information

Target Indication

Non-Small Cell Lung Cancer (NSCLC)

Clinical Trial

NCT05801029

Last updated: 10/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

AZN

AstraZeneca PLC

Pharmaceutical Preparations•Europe•NASDAQ

Related Pipeline

Niraparib plus Abiraterone acetate plus PrednisonePhase 3

Metastatic Castration-resistant Prostate Cancer (mCRPC)

ChemotherapyPhase 3

Anticancer Treatment

AZD6234Phase 3

Obesity/Overweight

AZD1152Phase 3

Acute Myeloid Leukemia

Saruparib (AZD5305)Phase 3

Ovarian Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts